Navigation Links
Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
Date:6/19/2009

dification or additional methods may need to be developed, the success of which is not assured, due to possible future changes in the L-DOS47 formulation or manufacturing process, requirements of regulatory authorities, or other factors; the need to further upscale the manufacturing process for the Company's drug candidates and the risk that further upscaling may not be achieved within the timelines expected by the Company or at all; the need for regulatory approvals, which may not be obtained in a timely manner or at all; the need for clinical trials, the occurrence and success of which cannot be assured; intellectual property risks; marketing/manufacturing risks and partnership/strategic alliance risks, including Helix's dependency on KBI Biopharma Inc. and its other contractors, consultants and advisors, whose performance and interdependence can critically affect the Company's performance and the achievement of its milestones; product liability risks; the effect of competition; the risk of technical obsolescence; and the risk of changes in business strategy or development plans. Such risks and uncertainties, and others affecting the Company which could cause actual results to vary materially from current results or those anticipated in forward-looking statements and information, are more fully described in the Company's latest Annual Information Form, MD&A and other reports filed with the Canadian Securities Regulatory Authorities from time to time at www.sedar.com, and in the Company's Form 20-F and other reports filed with the U.S. SEC from time to time (see www.sec.gov/edgar.shtml). Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should tho
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
2. Helix BioPharma to Present at the BioFinance 2009 Conference
3. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
4. Helix BioPharma Announces Q2 2009 Financial Results
5. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
6. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
7. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
8. Helix BioPharma Announces Q1 2009 Financial Results
9. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
10. Helix BioPharma Corp. Announces Fiscal 2008 Results
11. Helix Biopharma Closes $11.4 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- InferMed , s ... will augment ... olutions suite   Elsevier , a ... services, announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the ...
(Date:7/1/2015)... July 1, 2015  UCB, a multinational biopharmaceutical ... global leader in designing, transforming, and running intelligent ... in recognition of their close collaboration in driving ... global business services (GBS) finance organization. ... clients that work together effectively to embrace the ...
(Date:6/30/2015)... - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that ... approved the resolutions relating to: (i) a private ... at a price of $2.67 per unit (the ... one common share and 0.075358 common share purchase ... and (ii) the amendment to Resverlogix,s articles to ...
(Date:6/30/2015)... 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ... therapeutics that address unmet medical needs in women,s ... will present at the Cantor Fitzgerald Inaugural ... 2015Time: , 4:45 PM EDTLocation: , Le Parker ... , www.juniperpharma.com, under  ,Investor, or  click ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... CAMBRIDGE, Mass., Aug. 25 Peptimmune, Inc., ... a clinical trial to evaluate the safety, tolerability, pharmacokinetics, ... Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide ... autoimmune diseases. , , The Phase ...
... CITY, Aug. 25 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: ... effective and affordable vaccines based on proprietary manufacturing ... it has received clearance from Health Canada to ... its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrollment ...
... , SAN MATEO, Calif., Aug. 25 ... on developing and commercializing novel pain management therapies, today announced the ... a director and Audit Committee chairman, effective August 20, 2009. Mr. ... company focused on exploiting a novel, Nobel Prize winning method of ...
Cached Biology Technology:Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 2Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 3NeurogesX Appoints New Board Director and Audit Committee Chairman 2NeurogesX Appoints New Board Director and Audit Committee Chairman 3NeurogesX Appoints New Board Director and Audit Committee Chairman 4NeurogesX Appoints New Board Director and Audit Committee Chairman 5
(Date:6/17/2015)... PALM BEACH GARDENS, Fla. , June 17, ... identity management solutions, today announced that its U.are.U ... by Togo,s Eateries, Inc., ... based fast casual sandwich chain, to increase security, ... (POS). The Crossmatch fingerprint readers enable instant, non-repudiable identity ...
(Date:6/16/2015)... Fingerprint Cards has received an order of 375 ... from one of its module partners in Asia ... the third quarter 2015. The sensors will be used by ... Jörgen Lantto, CEO of FPC, comments: " This order   ... smartphone OEMs in integrating touch fingerprint sensors in   their ...
(Date:6/15/2015)... , June 15, 2015 A new ... Telstra reveals the majority of US consumers using mobile banking ... biometrics, such as fingerprint and voiceprint, instead of having to ... According to Telstra,s " Mobile Identity   -   The ... report, with smartphones now the primary channel used by Gen ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... Michigan State University researchers looking at the effects of ... calorie-restricted diet were more likely to die after being ... While research suggests inflammation associated with obesity ... the study results revealed a low-calorie diet may actually ...
... on the BP Deepwater Horizon drilling rig in the Gulf ... to understand the impact that this disaster has had on ... at a rate of approximately 53,000 barrels per day before ... study confirms that oil from the Macondo well made it ...
... is now open for the forthcoming International Polar Year ... 22-27 April 2012, Montral, Canada The IPY 2012 ... the largest and most important scientific conferences for polar ... thought-provoking panel discussions and workshops will provide the focal ...
Cached Biology News:Low-calorie diet may be harmful for bowel disease patients 2Study confirms oil from Deepwater Horizon disaster entered food chain in the Gulf of Mexico 2International Polar Year conference: From knowledge to action 2
... conserved form of cell suicide, which follows ... component of this process is a cascade ... enzymes participate in a series of reactions ... signals and result in the cleavage of ...
...
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Biology Products: